The Influence of Monoclonal Antibodies to Human Endoglin on the Functional Characteristics of EA.hy926 Endothelial Cells

被引：2

作者：

Stolbovaya A.Y. ^{[1
]}

Smirnov I.V. ^{[1
]}

Pinevich A.A. ^{[1
,2
]}

Berlina M.A. ^{[1
]}

Kozyreva A.R. ^{[3
]}

Shashkova O.A. ^{[1
]}

Sokolov D.I. ^{[3
]}

Selkov S.A. ^{[3
]}

Samoilovich M.P. ^{[1
,2
]}

机构：

[1] Russian Research Center for Radiology and Surgical Technologies named after academician A. M. Granov, Ministry of Health of Russia, St. Petersburg

[2] Saint-Petersburg State University, St. Petersburg

[3] The Research Institute of Obstetrics, Ginecology and Reproductology named after D. O. Ott, Ministry of Health of Russia, St. Petersburg

来源：

Cell and Tissue Biology | 2020年 / 14卷 / 1期

基金：

俄罗斯基础研究基金会;

关键词：

adhesion; CD105; cell migration; EA.hy926; endoglin; endothelium; monoclonal antibody; soluble endoglin;

D O I：

10.1134/S1990519X20010095

中图分类号：

学科分类号：

摘要：

Abstract: The endothelium of blood vessels plays an important role in the regulation of normal and pathological processes occurring in the tissues. Monoclonal antibodies (MAbs) to endoglin (CD105), a marker of endothelial cells, are considered as potential agents to affect the functional characteristics of endothelial cells. Here, we report the ability of MAbs against several epitopes of endoglin to modify the functional characte-ristics of human EA.hy926 endothelial cells in vitro. Different MAbs were found to slow down cell proliferation or migration, to increase the adhesion of monocyte-like cells, or to reduce the rate of soluble endoglin accumulation in a culture medium. Two MAbs of the eight studied reagents were able to affect several functional characteristics of endothelial cells. © 2020, Pleiades Publishing, Ltd.

引用

页码：1 / 15

页数：14

共 50 条

[1]

Ahn K., Pan S., Beningo K., Hupe D., A permanent human cell line (EA.hy926) preserves the characteristics of endothelin converting enzyme from primary human umbi-lical vein endothelial cells, Life Sci, 56, pp. 331-2341, (1995)

[2]

Apolo A.B., Karzai F.H., Trepel J.B., Alarcon S., Lee S., Lee M.J., Tomita Y., Cao L., Yu Y., Merino M.J., Madan R.A., Parnes H.L., Steinberg S.M., Rodriguez B.W., Seon B.K., Gulley J.L., Arlen P.M., Dawson N.A., Figg W.D., Dahut W.L., A Phase II Clinical trial of TRC105 (anti-endoglin antibody) in adults with advanced/metastatic urothelial carcinoma, Clin. Genitourin. Cancer, 15, pp. 77-85, (2016)

[3]

Barbara N.P., Wrana J.L., Letarte M., Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily, J. Biol. Chem, 274, pp. 584-594, (1999)

[4]

Barry F.P., Boynton R.E., Haynesworth S., Murphy J.M., Zaia J., The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105), Biochem. Biophys. Res. Commun, 265, pp. 134-139, (1999)

[5]

Bates D., Machler M., Bolker B., Walker S., Fitting linear mixed-effects models using Lme4, J. Stat. Soft, 67, pp. 1-48, (2015)

[6]

Bouis D., Hospers G.A., Meijer C., Molema G., Mulder N.H., Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research, Angiogenesis, 4, pp. 91-102, (2002)

[7]

Carmeliet P., Jain R.K., Molecular mechanisms and clinical applications of angiogenesis, Nature, 473, pp. 298-307, (2011)

[8]

Conley B.A., Koleva R., Smith J.D., Kacer D., Zhang D., Bernabeu C., Vary C.P., Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain, J. Biol. Chem, 279, pp. 27440-27449, (2004)

[9]

Dolinsek T., Markelc B., Bosnjak M., Blagus T., Prosen L., Kranjc S., Stimac M., Lampreht U., Sersa G., Cemazar M., Endoglin silencing has signi-ficant antitumor effect on murine mammary adenocarcinoma mediated by vascular targeted effect, Curr. Gene Ther, 15, pp. 228-244, (2015)

[10]

Duffy A.G., Ulahannan S.V., Cao L., Rahma O.E., Makarova-Rusher O.V., Kleiner D.E., Fioravanti S., Walker M., Carey S., Yu Y., Venkatesan A.M., Turkbey B., Choyke P., Trepel J., Bollen K.C., Steinberg S.M., Figg W.D., Greten T.F., A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on Sorafenib, United Eur. Gastroenterol. J., 3, pp. 453-461, (2015)

← 1 2 3 4 5 →